Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

Hardik Goswami (), Adnan Alsumali, Yiling Jiang, Matthias Schindler, Elizabeth R. Duke, Joshua Cohen, Andrew Briggs and Amy Puenpatom
Additional contact information
Hardik Goswami: BARDS-Health Economics and Decision Science, Merck & Co, Inc.
Adnan Alsumali: BARDS-Health Economics and Decision Science, Merck & Co, Inc.
Yiling Jiang: BARDS-Health Economics and Decision Science MSD (UK) Ltd
Matthias Schindler: BARDS-HTA, MSD Ltd
Elizabeth R. Duke: Fred Hutchinson Cancer Research Center
Joshua Cohen: Center for the Evaluation of Value and Risk in Health
Andrew Briggs: London School of Hygiene and Tropical Medicine
Amy Puenpatom: BARDS-Health Economics and Decision Science, Merck & Co, Inc.

PharmacoEconomics, 2023, vol. 41, issue 5, No 9, 605-605

Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01263-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:41:y:2023:i:5:d:10.1007_s40273-023-01263-w

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01263-w

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().